KUO, Tracy Chia-Chien,CHAPARRO RIGGERS, Javier Fernando,CHEN, Wei,CHEN, Amy Shaw-Ru,PASCUA, Edward Derrick,VAN BLARCOM, Thomas John,BOUSTANY, Leila Marie,HO, Weihsien,YEUNG, Yik Andy,STROP, Pavel,RAJP
申请号：
PE2017002104
公开号：
PE20180046A1
申请日:
2016.03.30
申请国别(地区):
PE
年份:
2018
代理人:
摘要：
It refers to a kind of isolated antibody, or an antique combined with a part of it, which specifically combines a B-cell mature antibody (BCMA),The antibody includes: (a) a variable heavy chain region (VH), including: (I) a region for determining complementarity (CDR1), including amino acid sequence SEQ ID No: 301, SEQ ID No: 302, or ID No: 303； (II) VH CDR2, including SEQ ID No: 305, or SEQ ID No: 306； and (III) a CDR3. VH includes SEQ ID No: 307, SEQ ID No: 308； (b) a light chain variable area, including: (I) VL CDR1, including SEQ ID No: 309, (II) VL CDR2, including SEQ ID No: 310, and (III) VL CDR3, including SEQ ID No: 311,Or an unidentified number 312 It is more closely related to a number of heteroantibodies, specifically the third differential group (CD3) and a cell tumor antigen (e.g., bisexual antibodies specifically combined with the third and BCMA). He also mentioned a pharmacosynthesis, an isolated multiribose, a vector and a hollow cell phone. This kind of biological specific antibody is useful as a kind of medicine to treat cancer, such as multiple myeloma, plasma cell malignant tumor and so on.Se refiere a un anticuerpo aislado, o un antigeno que se une a un fragmento del mismo, que se une especificamente un antigeno de maduracion de celulas B (BCMA), en donde el anticuerpo comprende: (a.) una region variable de cadena pesada (VH) que comprende: (i) una region determinante de la complementariedad uno (CDR1) que comprende la secuencia de aminoacidos SEQ ID NO: 301, SEQ ID NO: 302,o SEC ID NO: 303； (ii) una CDR2 de VH que comprende la secuencia SEQ ID NO:305,o SEQ ID NO: 306； y (iii) una CDR3 de VH que comprende la secuencia SEQ ID NO: 307, SEQ ID NO: 308； (b.) una region variable de cadena ligera (VL) que comprende: (i) una CDR1 de VL que comprende la secuencia de aminoacidos SEQ ID NO: 309, (ii) una CDR2 de VL que comprende la secuencia SEQ ID NO: 310, Y (iii) una CDR3 de VL que comprende la secuencia de aminoacidos SEQ ID NO: 311, O SEQ ID NO: 312
